Ignite Creation Date:
2025-12-25 @ 12:32 AM
Ignite Modification Date:
2026-01-04 @ 8:39 AM
Study NCT ID:
NCT02091167
Status:
COMPLETED
Last Update Posted:
2019-06-24
First Post:
2014-03-16
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Bilateral Prefrontal Modulation in Crack-cocaine Addiction
Sponsor:
Federal University of Espirito Santo
Organization:
Study Overview
Official Title:
Prefrontal Modulation by Repetitive Bilateral Transcranial Direct Current Stimulation (tDCS) in Crack-cocaine Addicted Inpatients.
Status:
COMPLETED
Status Verified Date:
2019-03
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
tDCS_CRACK
Brief Summary:
In this study, eligible crack-cocaine addicted inpatients recruited from specialized clinics for substance abuse disorder treatment, filling inclusion criteria and not showing any exclusion criteria, were randomized to receive the repetitive (10 sessions, every other day) bilateral dorsolateral Prefrontal Cortex (dlPFC: cathodal left / anodal right) tDCS (2 milliamperes, 3x7 cm2, for 20 min) or placebo (sham-tDCS). Craving to the use of crack-cocaine was examined before (baseline), during and after the end of the tDCS treatment.
Based in our previous data, our hypothesis was that repetitive bilateral tDCS over dlPFC would favorably change clinical, cognitive and brain function in crack-cocaine addiction and these would be long-lasting effects.
Based in our previous data, our hypothesis was that repetitive bilateral tDCS over dlPFC would favorably change clinical, cognitive and brain function in crack-cocaine addiction and these would be long-lasting effects.
Detailed Description:
Before (baseline) and after tDCS or sham-tDCS treatment, subjects were examined:
(1) clinically, regarding craving (obsessive compulsive scale) and relapses to the drug use.
They were followed-up for clinical examination at least 60 days after treatment.
(1) clinically, regarding craving (obsessive compulsive scale) and relapses to the drug use.
They were followed-up for clinical examination at least 60 days after treatment.
Study Oversight
Has Oversight DMC:
False
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
Secondary ID Infos
| Secondary ID | Type | Domain | Link | View |
|---|---|---|---|---|
| CNPq_ 475232/2013-5 | OTHER_GRANT | CNPq process # 475232/2013-5 | View |